Clinical Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia With the t(4;ll) (q21;q23) By Ching-Hon Pui, Lawrence S. Frankel,

Slides:



Advertisements
Similar presentations
Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.
Advertisements

TA OGUNLESI (FWACP)1 CHILDHOOD LEUKAEMIA. TA OGUNLESI (FWACP)2 LEUKAEMIA Heterogenous group of malignant disorders Characterised by uncontrolled clonal.
A Hematology Case Study about Leukemia by Sarah Wycoff
LEUKEMIA—HEMATOLOGY {S1}
ECSI case Fall 2014 Andrea M. Sheehan, MD Associate Professor of Pathology & Immunology Baylor College of Medicine.
Leukemias.
Targeted Therapies Against Lymphocyte Signaling Pathways in Childhood Leukemia Stuart S. Winter, MD Pediatric Hematology/Oncology The T. John Gribble Endowed.
Introduction to leukemia
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
Acute lymphoblastic leukemia (ALL)
Leukemia Maturation of Myeloid Cells Dr. Rania Alhady.
Identification and Diagnosis of the Acute Leukemias
LEUKEMIAS Dr Mehboob Khan Pathologist
Chapter 17 Chronic Leukemias.
Chronic Leukemia Dr. Rania Alhady Chronic Lymphocytic leukemia (CLL):
Flow Cytometric Abnormalities in Myelodysplastic Syndrome Raida Oudat,MD Consultant Hematopathologist at Princess Iman Research and Laboratory Sciences.
In The name of God.  CD117 is a 145 kD protein tyrosine kinase also known as c- Kit.  Receptor for stem cell factor or c-Kit ligand.  CD117 is expressed.
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.
Heterogeneity of Abnormal RUNX1 Leading to Clinicopathological Variations in Childhood B-Lymphoblastic Leukemia Xiayuan Liang, MD Department of Pathology.
Acute Leukemia and the FLT3 Receptor B y: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
Leukemia.
CLINICAL LABORATORY DIAGNOSTICS OF HEMOBLASTOSIS
4th Year Medical Student KAU
Chronic leukemia 1. Chronic Lymphocytic leukemia (CLL) * Definition: Chronic neoplastic disorder characterized by accumulation of small mature-looking.
Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients with Isolated Trisomy 13 Fehniger TA et al. Blood 2009;113(5):
..  Neoplastic proliferation of small mature appearing  lymphocytes and account 25% of leukemia  It is rare before 40 years of age, the median age.
MLAB 1415: Hematology Keri Brophy-Martinez
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
MLAB Hematology Keri Brophy-Martinez
Hematopoetic Cancers. Hematopoesis Leukemia New diagnoses each year in the US: 40, 800 Adults 3,500 Children 21,840 died of leukemia in 2010.
Acute Leukemia Kristine Krafts, M.D..
Introduction: The clinical features of neoplasia are due to capacity of tumor cells to proliferate. Neoplastic cells often have an abnormal DNA content.
Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
LEUKEMIA Dr. Omar Alshaer. Acute Leukemia.
Acute lymphoblastic leukemia in children
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
Hematology There are four lectures: 1.Acute leukemias (2 hours). 2.Chronic leukemias (2 hours).
Society for Hematopathology/European Association for Haematopathology 2013 Case Number 208 Erika Moore, MD; Darshan Roy, MD; Patti Cohen, MD; Adam Bagg,
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
SH/EAHP 2013 Workshop Case 285 Sara-Eloína Cuadra-Acree, MD,* Kiran Qidwai, MD,* Brit Shackley, MD,** & Imran N. Siddiqi, MD, PhD* * University of Southern.
CASE 411 Jose Gonzalez-Berjon, MD & Tariq Muzzafar, MD UT M.D. Anderson Cancer Center.
Acute Leukemia Kristine Krafts, M.D..
eCSI case 2 – November 2016 Jyotinder Nain Punia, MD
CASE SUBMISSION 2016 EAHP BM Workshop
Acute Myeloid Leukemia
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
Cells Maturation in Bone Marrow.
11 th lecture Chronic myeloid leukaemia By DR Fatehia Awny Faculty of Health Science Beirut Arab University
Early T-Cell Precursor ALL in 5 Year Old Female
STUDY ON FEATURES OF CLINIC, BIOCLINIC AND DIAGNOSIS THE SUBTYPE OF ACUTE LEUKEMIA IN VIETTIEP FRIENDSHIP HOSPITAL, Dr: Pham Thi Loc Hematology.
by Michele Paessler, and John Choi
Chronic Leukemia Kristine Krafts, M.D..
Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.
IMMUNOPHENOTYPING LEUKEMIAS AND LYMPHOMAS
Lymphoid Preponderance and the Absence of Basophilia
بسم الله الرحمن الرحيم Acute lymphoid leukemia(ALL) Prepared by ::
Donor Cell Leukemia in Umbilical Cord Blood Transplant Patients
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.
Case study.
Leukemia case (18).
Case study A 36-year-old woman presented with a two-month history of increasing fatigue and abdominal fullness with accompanying loss of appetite. There.
Neoplastic disorder.
RITUXIMAB IN B-LINEAGE ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA
Introduction Results Materials and Methods Conclusions References 1
HOXB6 overexpression results in delayed AML
Kantarjian HM et al. Blood 2008;112:Abstract 635.
Presentation transcript:

Clinical Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia With the t(4;ll) (q21;q23) By Ching-Hon Pui, Lawrence S. Frankel, Andrew J. Carroll, Susana C. Raimondi, Jonathan J. Shuster, David R. Head, William M. Crist, Vita J. Land, D. Jeanette Pullen, C. Philip Steuber, Frederick G. Behm, and Michael J. Borowitz

INTRODUCTION  Acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer. leukemias.  Leukemia is a cancer of the blood or bone marrow.  It is characterized by an abnormal proliferation (production by multiplication) of blood cells, usually white blood cells white blood cellswhite blood cells

Four major kinds of leukemia Cell type AcuteChronic Lymphocytic leukemia or lymphoblastic Acute lymphoblastic Acute lymphoblastic leukemia (ALL) Chronic lymphocytic leukemia Chronic lymphocytic leukemia (CLL ) Myelogenous leukemia also myeloid or nonlymphocytic Acute myelogenous Acute myelogenous leukemia (AML ) Chronic myelogenous leukemia Chronic myelogenous leukemia (CML) Acute leukemiaAcute leukemia is characterized by the rapid increase of immature blood cells.

Immunological classification of ALL Type of ALL HLA- DR TdTCD10 CD19 a CyIgSIgCD7cCD3 Pro-B- ALL CommonALL Pre-B- ALL B-ALL+0+/-++/-++00 Eerly-T- ALL 0+0/ T-ALLb0+0/+000++

French-American-British (FAB) Classification  L1 Small homogeneous with scanty cytoplasm, moderate basophilia, inconspicuous nuclei.  L2 Larger, heterogeneoys cells, variable cytoplasm, basophilia, prominent nuclei.  L3 Larger, heterogeneoys cells, with dark basophilic cytoplasm, prominent vacules, prominent nuclei.

A translocation involving the long arms of chromosomes 4 and 11- t((4;11)(q21;q23) has been observed in patients with ALL. In a recent review, it was reported that t(4;11) has been observed in 60% of lymphoblastic leukemias in children under the age of 1 year. t(4;11)(q21;q23) ) G-banding (left) - Courtesy Diane H. Norback, Eric B. Johnson, and Sara Morrison- Delap, UW Cytogenetic Services; R- banding (right) - Editor (above), and Courtesy Christiane Charrin (belowUW Cytogenetic Services

Aim of the study  In here, a Collaborative Study of 40 Cases with the t(4;11)(q21;q23) chromosomal abnormality was studied in children with newly diagnosed acute lymphoblastic leukemia (ALL).  This study describe : - The frequency, - The frequency, - Clinical and laboratory features, - Clinical and laboratory features, - And treatment outcome in these 40 cases - And treatment outcome in these 40 cases with t(4;11) )(q21;q23). with t(4;11) )(q21;q23).

SUBJECTS n = 2,724 N = 515 N = 40 N = Total Therapy Studies at St Jude Children's Research Hospital (SJCRH) Pediatric Oncology Group (POG) studies The total number accrued t((4;11)(q21;q23) Have the t((4;11)(q21;q23) were studied

Methods  Morphologic studies -Cases were classified according to French- American-British (FAB) based on bone marrow cell morphology and cytochemical staining characteristics,. -Cases were classified according to French- American-British (FAB) based on bone marrow cell morphology and cytochemical staining characteristics,.  Ficoll-Hypaque gradient : -Bone marrow cells were separated by this method. -Bone marrow cells were separated by this method.

 Flow cytometry -Cell surface antigens were detected -Cell surface antigens were detected by a standard indirect immuno - by a standard indirect immuno - fluorescence assay. fluorescence assay. -were considered positive if they were expressed in 20% or more of the blast cells. -were considered positive if they were expressed in 20% or more of the blast cells. A simplified illustration of Flow Cytometry (Gerstner et al., 2005)

With flowcytometry monoclonal antibodies was used to : With flowcytometry monoclonal antibodies was used to : - lymphoid- associated antigens (CD2, CD5, CD7, CD19, CD20, - lymphoid- associated antigens (CD2, CD5, CD7, CD19, CD20, CD21, CD22, and CD24), CD21, CD22, and CD24), -Myeloid-associated antigens (CD13, CD15, and CD33), and -Myeloid-associated antigens (CD13, CD15, and CD33), and -Nonlineage specific antigens (CD10, CD34, CD45, and HLA-DR). -Nonlineage specific antigens (CD10, CD34, CD45, and HLA-DR). Cells were also tested for cytoplasmic Ig (cIg). Cells were also tested for cytoplasmic Ig (cIg). -Significant cIg expression was defined by the presence -Significant cIg expression was defined by the presence of Ig in the cytoplasm of 10% or more of blasts. of Ig in the cytoplasm of 10% or more of blasts.

Chromosome analysis was done as follows: Processing of only 0.1 ml of sedimented cells or of sedimented cells or less per centrifuge tube. less per centrifuge tube. Exposure of cells to Colcemid to Colcemid for a maximum of 25 min. for a maximum of 25 min. Control of the total time of time of exposure to hypotonic solution. Slide preparation by a specific by a specificedging-flaming technique. technique. The cells were cultured in RPMI 1640 medium. Supplemented with 30% fetal calf serum, to support cellular activity with 30% fetal calf serum, to support cellular activity during specimen transport during specimen transport 1 2 3

- This procedure were finalized by doing natural aging of the slides to achieve optimal drying and use of a modified G-banding procedure that employs Wright's stain. employs Wright's stain.

Results  Of the 1,986 cases studied, 40 (2%) were found to have a leukemic cell line with the t(4;11)(q21;q23). These children (25 girls and 15 boys) ranged in age from 1 month to 14 years 8 months at diagnosis (median, 9 months).  Clinical and Laboratory findings as in the following table:

Cell Immunophenotyping

Discussion  The reported frequency of the t(4;ll) in patients with ALL has ranged from 1.6% to 11% for children, and from 5% to 8% for adults In our study, this chromosomal abnormality occurred in 2%, Thus, the t(4;ll) is one of the most common specific chromosomal translocations in childhood ALL. In our study, this chromosomal abnormality occurred in 2%, Thus, the t(4;ll) is one of the most common specific chromosomal translocations in childhood ALL.  Our patients aged 1 to 9 years had a significantly better treatment outcome than infants and older patients with the t(4;ll). Seven of eight patients in this age group, compared with 9 of the 32 other patients, remain in remission. Thus, the adverse prognosis of the t(4;ll) is related at least in part to its association with the poor-risk age groups. Seven of eight patients in this age group, compared with 9 of the 32 other patients, remain in remission. Thus, the adverse prognosis of the t(4;ll) is related at least in part to its association with the poor-risk age groups.

 Ultrastructural, immunophenotypic, and in vitro culture studies have demonstrated marked lineage heterogeneity in cases with the t(4;ll). -Although many reported cases have had myelomonocytic characteristics, or mixed lineage marker expression most have been classified as B-precursor-cell ALL (CD19+, HLA-DR+). -Although many reported cases have had myelomonocytic characteristics, or mixed lineage marker expression most have been classified as B-precursor-cell ALL (CD19+, HLA-DR+). -Only rarely have or B-cell" phenotypes been reported in patients with this translocation. Indeed, all 35 evaluable cases in this study had B-precursor-cell ALL. -Only rarely have or B-cell" phenotypes been reported in patients with this translocation. Indeed, all 35 evaluable cases in this study had B-precursor-cell ALL. -During this study period, they have not encountered any case of acute myeloid leukemia with the t(4;ll). -During this study period, they have not encountered any case of acute myeloid leukemia with the t(4;ll).

Conclusion  The t(4;ll) is one of the most common nonrandom translocations in childhood ALL, accounting for 2% of newly diagnosed cases.  Cases with the t(4;ll) are associated with female sex, very young age at presentation, hyperleukocytosis, the CDlO - /CD15 + /CD19 + / CD24 -/+ immunophenotype, and poor treatment outcome for infants and patients aged ≥ 10 years.  Additional studies are clearly merited to determine the independent prognostic significance of the t(4;ll) and to assess possible molecular differences in this translocation for different age groups.